Provided by Tiger Trade Technology Pte. Ltd.

Atara Biotherapeutics

9.70
+0.32003.41%
Post-market: 9.700.00000.00%19:30 EDT
Volume:27.09K
Turnover:259.11K
Market Cap:97.37M
PE:-8.16
High:9.89
Open:9.46
Low:9.15
Close:9.38
52wk High:19.15
52wk Low:3.92
Shares:10.04M
Float Shares:4.73M
Volume Ratio:0.50
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1889
EPS(LYR):2.57
ROE:-2014.86%
ROA:-24.14%
PB:-2.63
PE(LYR):3.77

Loading ...

Atara Biotherapeutics jumps 70%, or $3.60, to $8.75

TIPRANKS
·
May 08

Atara Biotherapeutics trading resumes

TIPRANKS
·
May 08

BUZZ-U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise

Reuters
·
May 08

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:50 AM

Reuters
·
May 07

BUZZ-Atara jumps after US FDA backs re-submission of cancer drug application

Reuters
·
May 07

Atara Biotherapeutics Shares Jump 42% After US FDA Backs Resubmission of Co's Cancer Drug Application

THOMSON REUTERS
·
May 07

Atara Biotherapeutics Gains Clearer FDA Path for Tab-cel

TIPRANKS
·
May 07

Why Is Atara Biotherapeutics Stock (ATRA) Up Today?

TIPRANKS
·
May 07

BRIEF-Atara Biotherapeutics Provides Regulatory Update On Tabelecleucel

Reuters
·
May 07

Atara Biotherapeutics Inc - FDA Agrees Single Arm Study May Support Future Tab-Cel Marketing Application

THOMSON REUTERS
·
May 07

Atara Biotherapeutics Inc - Expects Further Tab-Cel Regulatory Update in Third Quarter

THOMSON REUTERS
·
May 07

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

THOMSON REUTERS
·
May 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 06

Atara Biotherapeutics Receives Nasdaq Non-Compliance Delisting Notice

TIPRANKS
·
May 02

Atara Biotherapeutics risks Nasdaq delisting after market value falls below $50 million threshold

Reuters
·
May 02

Atara Biotherapeutics announces annual shareholder meeting via virtual webcast

Reuters
·
Apr 25

Atara Biotherapeutics Faces Securities Lawsuit After FDA Setbacks and Sharp Stock Declines Tied to Tabelecleucel

TIPRANKS
·
Apr 17

Analysts Offer Insights on Healthcare Companies: Sight Sciences (SGHT), Atara Biotherapeutics (ATRA) and Rezolute (RZLT)

TIPRANKS
·
Mar 30

Atara Biotherapeutics Faces Federal Securities Lawsuit Over Alleged Misstatements About Drug Approval Prospects

TIPRANKS
·
Mar 28

Atara Biotherapeutics Q4 EPS $(0.25) Beats $(0.44) Estimate, Sales $1.595M Miss $2.671M Estimate

Benzinga Earnings
·
Mar 17